The present invention provides an application of a fusion polypeptide of ziconotide and TAT peptide in preparation of a medication. In the present invention, a fusion peptide is obtained by connecting the C terminal of ziconotide with the N terminal of a cell membrane penetrating peptide, and thus, the defects that intramuscular injection cannot be realized and the like are overcome. The fusion polypeptide can pass through a blood-brain barrier and is applicable for intravenous administration, intraperitoneal administration, or intranasal administration; the operation is convenient and clinical risk is low; after being intravenously, intraperitoneally or intranasally applied, the fusion polypeptide has long pharmacodynamic action time in vivo, has a good analgesic effect and fewer peptide side effect, and is applicable for large-scale clinical application. The fusion polypeptide of the present invention is simple to prepare, a preparation process and quality during preparation are controllable, and the fusion polypeptide is applicable for large-scale industrial production.
展开▼
